Vizcarra, Joaquin A.
Situ-Kcomt, Miguel
Artusi, Carlo Alberto
Duker, Andrew P.
Lopiano, Leonardo
Okun, Michael S.
Espay, Alberto J.
Merola, Aristide http://orcid.org/0000-0002-5587-726X
Article History
Received: 18 May 2018
Revised: 7 June 2018
Accepted: 11 June 2018
First Online: 16 June 2018
Compliance with ethical standards
:
: The manuscript does not contain clinical studies or patient data.
: Dr. Vizcarra reports no conflict of interest. Dr. Situ-Kcomt reports no conflict of interest. Dr. Artusi reports no conflict of interest. Dr. Duker has previously received honoraria but has not received industry support in the last 36 months. Dr. Lopiano has received honoraria for lecturing and travel grants from Medtronic, UCB Pharma, and AbbVie. Dr. Okun serves as a consultant for the National Parkinson Foundation, and has received research grants from NIH, NPF, the Michael J. Fox Foundation, the Parkinson Alliance, Smallwood Foundation, the Bachmann-Strauss Foundation, the Tourette Syndrome Association, and the UF Foundation. His DBS research is supported by: R01 NR014852 and R01NS096008. He has previously received honoraria, but, in the past > 60 months, he has received no support from industry. He has received royalties for publications with Demos, Manson, Amazon, Smashwords, Books4Patients, and Cambridge (movement disorders books). He is an associate editor for New England Journal of Medicine Journal Watch Neurology. He has participated in CME and educational activities on movement disorders (in the last 36) months sponsored by PeerView, Prime, QuantiaMD, WebMD, Medicus, MedNet, Henry Stewart, and by Vanderbilt University. The institution and not Dr. Okun receives grants from Medtronic, Abbvie, Allergan, and ANS/St. Jude, and the PI has no financial interest in these grants. He has participated as a site PI and/or co-I for several NIH, foundation, and industry sponsored trials over the years but has not received honoraria. Dr. Espay has received grant support from the NIH, Great Lakes Neurotechnologies, and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, TEVA, Impax, Acadia, Acorda, Cynapsus/Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from Abbvie, UCB, USWorldMeds, Lundbeck, Acadia, the American Academy of Neurology, and the Movement Disorders Society. He serves on the editorial boards of the Journal of Parkinson’s Disease and Parkinsonism and Related Disorders. Dr. Merola is supported by NIH (KL2 TR001426) and has received speaker honoraria from CSL Behring and Cynapsus Therapeutics. He has received grant support from Lundbeck.